Compare BRBS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | DCTH |
|---|---|---|
| Founded | 1893 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.3M | 350.7M |
| IPO Year | N/A | N/A |
| Metric | BRBS | DCTH |
|---|---|---|
| Price | $4.35 | $10.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | 220.8K | ★ 505.9K |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | ★ 5.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | 0.03 |
| Revenue | ★ $96,332,000.00 | $79,603,000.00 |
| Revenue This Year | N/A | $131.69 |
| Revenue Next Year | N/A | $39.22 |
| P/E Ratio | ★ $83.34 | $295.89 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $2.92 | $8.12 |
| 52 Week High | $4.79 | $18.23 |
| Indicator | BRBS | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 50.02 |
| Support Level | $4.24 | $9.69 |
| Resistance Level | $4.40 | $10.86 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 38.37 | 29.06 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance and others. It has three reportable business segments: commercial banking, mortgage banking, and holding company activities.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.